Analytical chemistry

Epsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansion

Retrieved on: 
Wednesday, May 1, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, University College Cork, University, CFO, Cancer, Analytical chemistry, Environmental science, Biomedical Research, Business, Molecular biology, Engineering, Bachelor of Science, Patient, Master of Science, Immunoglobulin E, MBA, CBO, Antibody, Drug discovery, Therapy, Partner, Management

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman.

Key Points: 
  • Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman.
  • Ashley brings over 25 years of experience leading business and strategy development, licensing and deal-making within the biopharmaceutical industry.
  • Most recently, Ashley served as VP of Business Development at RemedyBio, a discovery and development precision immunotherapy company.
  • Dr Tim Wilson, Chief Executive Officer of Epsilogen, commented: “I am delighted to welcome Ashley to the Epsilogen team.

Thermo Fisher Scientific Announces a New In-line Metrology Solution to Improve Battery Safety and Performance

Retrieved on: 
Wednesday, March 27, 2024
Research, Technology, Other Technology, Clinical Trials, Health Technology, Batteries, General Health, Health, Science, Other Science, Risk, Thermo Fisher Scientific, Multimedia, Analytical chemistry, Electrode, Electric battery

To address the needs of the rapidly growing battery market, Thermo Fisher Scientific today introduced the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer, which delivers full-width electrode mass loading measurement and provides battery manufacturers with the data needed to make better, safer batteries, more efficiently.

Key Points: 
  • To address the needs of the rapidly growing battery market, Thermo Fisher Scientific today introduced the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer, which delivers full-width electrode mass loading measurement and provides battery manufacturers with the data needed to make better, safer batteries, more efficiently.
  • In contrast, the LInspector Edge In-line Mass Profilometer measures the entire electrode in real-time, at full production speed offering more complete insights for battery manufacturers.
  • “Superior batteries, particularly for electric vehicles, are critical to society’s planned transition to clean energy,” said Miguel Faustino, president of Chemical Analysis at Thermo Fisher Scientific.
  • Find out how it could improve your electrode coating process at: www.thermofisher.com/LinspectorEdge

Politan Nominates Two Independent Candidates for Masimo Board

Retrieved on: 
Monday, March 25, 2024
Banking, Professional Services, Finance, Analytical chemistry, Biophysical environment, Health, Lead, Doctor of Philosophy, IP, M&A, Audit committee, Corporate spin-off, Audit, WHEN, WILL, Science, MASI, Stryker Corporation, Laboratory, Dentsply Sirona, Compensated emancipation, Common stock, Financial management, Knowledge, Broadcom Inc., Acquisition, Security (finance), Senior, INC, Avient Corporation, Annual general meeting, Separation, WALL, MIT, Common, Hope College, Stanford University, National academy, Government, COGS, Management

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Key Points: 
  • Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
  • Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated:
    “When shareholders overwhelmingly elected Michelle Brennan and me to the Masimo Board last year, we were optimistic we could work productively with the rest of the Board to drive positive change.
  • However, at this stage the Board has been provided zero details, and Politan has serious concerns given the lack of basic governance and oversight we have observed since joining the Board.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito, William Jellison and Darlene Solomon (collectively, the “Participants”).

Minister Champagne announces appointments to the Standards Council of Canada's Governing Council

Retrieved on: 
Monday, February 5, 2024
SCC, Policy, Doctor of Philosophy, International airport, Parnassa, Accreditation, Public policy, Standards New Zealand, Memorial University of Newfoundland, Engineering, Personal ordinariate, Analytical chemistry, The Honourable, Social media, Toronto-Dominion Bank, National Research Council Canada, Electrical engineering, McGill University, Economic Policy (journal), University, Development, Business, ASTM International, Electricity, Communication, Royal Bank, Crown, Chairperson, Business administration, National security, Concordia University, Global Affairs Canada, Research and development, Assistant, Banking in Canada, Carleton University, Cabinet, Management

OTTAWA, ON, Feb. 5, 2024 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced recent appointments to the Standards Council of Canada's (SCC) Governing Council.

Key Points: 
  • OTTAWA, ON, Feb. 5, 2024 /CNW/ - Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced recent appointments to the Standards Council of Canada's (SCC) Governing Council.
  • He has been involved in standards development since 1984 in information technologies engineering and, more recently, biodigital convergence.
  • "These appointments will enhance the SCC's ability to continue to be a leader in the global standards industry.
  • – The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry
    Follow Canada Business on social media for business-related news: (X) Twitter , Facebook , Instagram

Dr. Kaveh Kahen, Appointed President at Phenomenex

Retrieved on: 
Thursday, February 1, 2024
Analytical chemistry, Chromatography, Doctor of Philosophy, George Washington University, Indoxacarb, Research, PerkinElmer, SCIEX, Management

TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.

Key Points: 
  • TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.
  • Dr. Kahen returns to the Danaher Life Sciences platform with a wealth of experience.
  • He began his career at SCIEX and was responsible for designing and developing novel technologies and instruments.
  • Kaveh is renowned for driving profitable growth in the highly competitive life sciences, analytical testing, and lab equipment markets.

Dr. Kaveh Kahen, Appointed President at Phenomenex

Retrieved on: 
Thursday, February 1, 2024
Analytical chemistry, Chromatography, Doctor of Philosophy, George Washington University, Indoxacarb, Research, PerkinElmer, SCIEX, Management

TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.

Key Points: 
  • TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.
  • Dr. Kahen returns to the Danaher Life Sciences platform with a wealth of experience.
  • He began his career at SCIEX and was responsible for designing and developing novel technologies and instruments.
  • Kaveh is renowned for driving profitable growth in the highly competitive life sciences, analytical testing, and lab equipment markets.

Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO

Retrieved on: 
Tuesday, January 16, 2024
SMARCA2, Research, Biology, Analytical chemistry, Sanofi, TPD, SAN, University, Business development, Cancer, Evaluation, Takeda Pharmaceutical Company, Medicinal chemistry, CDK2, Pharmaceutical industry

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.

Key Points: 
  • SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.
  • "I look forward to working with Mike to advance our clinical-stage pipeline and progressing more TPD programs against important cancer targets into the clinic."
  • I am excited to lead Plexium and continue to build a leading TPD company focused on improving patients' lives."
  • Dr. Martin joined Takeda in 2012 and prior to his most recent role, he was President of Takeda Ventures, Inc., Takeda's corporate venture capital company.

Aitia Appoints Drug R&D Executive Jean-Michel Gries as President & Chief Operating Officer

Retrieved on: 
Tuesday, September 19, 2023
Clinical pharmacology, Analytical chemistry, Drug development, Doctor of Pharmacy, University, Causal AI, Statistics, Roche, MBA, Parexel, Doctor of Philosophy, CNS, Science, Paris-Sud University, Wharton School of the University of Pennsylvania, Novartis, Patient, Ophthalmology, Widener University Commonwealth Law School, Drug discovery, Paris Descartes University, GNS, Digital twin, AI, Pharmacology, ChromeOS, Fine chemical, Alcon, Causality (physics)

SOMERVILLE, Mass., Sept. 19, 2023 /PRNewswire/ -- Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced the appointment of Dr. Jean-Michel Gries as President & Chief Operating Officer.

Key Points: 
  • SOMERVILLE, Mass., Sept. 19, 2023 /PRNewswire/ -- Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced the appointment of Dr. Jean-Michel Gries as President & Chief Operating Officer.
  • Jean-Michel is an accomplished senior life science executive with a track record of innovative drug discovery, translational medicine, and clinical development, combining the science and business of drug development.
  • He comes with a wealth of unique experience in drug R&D from big pharma, CROs, and small biotechs.
  • "I look forward to bringing my expertise and working alongside Colin and the teams towards revolutionizing drug discovery and development and ultimately improving the lives of patients."

Group14 Technologies Appoints Chemical Industry Leader Dr. Kim Ann Mink to its Board of Directors

Retrieved on: 
Thursday, September 14, 2023
Duke University, Most, Analytical chemistry, University, Ernst & Young Entrepreneur of the Year Award, Dow, Doctor of Philosophy, Businessperson, Turnkey asset management program, Ford, Human, Research and development, Hamilton College, Wharton School of the University of Pennsylvania, Air Liquide, Phosphate, Chemical industry, Connection, Rohm, Haas, Growth, Silicon, Research, Woman, Widener University Commonwealth Law School, General Motors, Management, Chemistry

WOODINVILLE, Wash., Sept. 14, 2023 /PRNewswire/ -- Group14 Technologies, the leading global manufacturer and supplier of advanced silicon battery technology, today announced the appointment of Dr. Kim Ann Mink to its board as its second independent director. Dr. Mink's leadership and expertise in the chemical industry will be a crucial asset to support Group14's growth as it scales its global manufacturing capacity in the US, Asia and Europe.

Key Points: 
  • After more than three decades in large multinational chemical companies, Dr. Mink brings a unique industry perspective to the board.
  • "Group14 has been successful in commercializing a proven, protected and scalable technology that addresses a real market need," Dr. Mink said.
  • "With unparalleled industry experience as a leader at some of the most successful global chemical companies, Kim Ann is a dynamic, energetic and highly sought-after advisor, which makes her the perfect addition to strengthen Group14's board," said Rick Luebbe, CEO and co-founder of Group14 Technologies.
  • "As we gear up for company growth, Kim Ann will be a critical voice on the Group14 board as we execute on our long-term vision for the electrification of everything."

Nevada Copper Appoints Dr. Elaine Dorward-King to its Board of Directors

Retrieved on: 
Tuesday, September 5, 2023
Analytical chemistry, Newmont, Doctor of Philosophy, Nevada Copper Belt Railroad, NCU, Colorado State University, Pumpkin, FSE, Kennecott Utah Copper, History, Social Security Government Pension Offset, Sustainability, Executive Authority (External Relations) Act 1936, Mining, OTC, TSX, Kenmare Resources, ESG, Social, Maryville College, Rio Tinto, Gold

YERINGTON, Nev., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Nevada Copper Corp. (TSX: NCU) (OTC: NEVDF) (FSE: ZYTA) (“Nevada Copper” or the “Company”) is pleased to announce the appointment of Dr. Elaine Dorward-King to the Board of Directors of Nevada Copper effective September 1, 2023.

Key Points: 
  • YERINGTON, Nev., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Nevada Copper Corp. (TSX: NCU) (OTC: NEVDF) (FSE: ZYTA) (“Nevada Copper” or the “Company”) is pleased to announce the appointment of Dr. Elaine Dorward-King to the Board of Directors of Nevada Copper effective September 1, 2023.
  • Stephen Gill, Chairman of the Board of Directors of Nevada Copper, stated, “We are thrilled that Elaine has chosen to join Nevada Copper’s Board, adding her extensive history of leadership and achievements in sustainable development to our team.
  • Elaine joins Nevada Copper at a crucial time in the development cycle as we focus on and implement ESG initiatives through the restart and ramp up to sustained underground operations and further through the development of the open pit project.
  • Prior to that she held various leadership roles focused on environmental and sustainability programs for companies in the mining, environmental and chemical sectors.